公开(公告)号：US20150140590A1

公开(公告)日：2015-05-21

申请号：US14413760

申请日：2013-07-10

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Toru Hirota ,  Norihisa Shindo ,  Kazuki Kumada

IPC: C12Q1/37 ,  G01N33/50

CPC classification number: C12Q1/37 ,  C07K2319/01 ,  C07K2319/50 ,  C07K2319/60 ,  C12N9/6472 ,  C12Y304/22049 ,  G01N33/5011 ,  G01N33/542 ,  G01N2333/96466 ,  G01N2500/04

Abstract: Problem to be SolvedAn object of the present invention is to provide a separase sensor for visualizing separase activity in a living cell. Another object is to develop a function analysis system of cell division using the separase sensor and further obtain a simple screening method for an anticancer agent.SolutionThe separase sensor of the present invention has two types of fluorescent proteins different in fluorescence wavelength at both ends of an amino acid sequence containing a separase cleavage site and a localization-targeting sequence targeting to a specific site within a cell. Since timing of activating separase and location of separase in a cell can be specified by use of the sensor, cell division can be analyzed and an anticancer agent can be screened.

Abstract translation: 要解决的问题本发明的目的是提供一种用于在活细胞中可视化分离酶活性的分离酶传感器。 另一个目的是开发使用分离酶传感器的细胞分裂功能分析系统，并进一步获得抗癌剂的简单筛选方法。 解决方案本发明的分离酶传感器具有两种类型的荧光蛋白，它们在含有分离酶切割位点的氨基酸序列的两端的荧光波长和靶向细胞内特定位点的定位靶向序列。 由于可以通过使用传感器来指定活化分离酶的定时和分离酶的位置，因此可以分析细胞分裂并筛选抗癌剂。

公开(公告)号：US20150111888A1

公开(公告)日：2015-04-23

申请号：US14398301

申请日：2013-04-30

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Ryoji Yao ,  Hiroyuki Osada ,  Yasumitsu Kondoh

IPC: C07D407/04 ,  C07D401/14 ,  C07D403/14 ,  C07D311/16

CPC classification number: C07D405/14 ,  A61K31/37 ,  A61K31/4025 ,  A61K31/4409 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/5377 ,  C07D311/16 ,  C07D401/14 ,  C07D403/14 ,  C07D407/04

Abstract: The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents.

Abstract translation: 本发明提供了靶向TACC3的小化合物。 本发明还提供了一种药物，特别是抗癌剂，其包含靶向TACC3的小化合物。 由通式（I）表示的化合物或其药学上可接受的盐，溶剂化物或酯衍生物与TACC3结合并抑制细胞生长。 因此，这些化合物可以用作药物，特别是抗癌剂。

公开(公告)号：US20240426809A1

公开(公告)日：2024-12-26

申请号：US18750552

申请日：2024-06-21

Applicant: TOPPAN Holdings Inc. ,  JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Yuki TAKAHASHI ,  Yuma YOKOKAWA ,  Ryohei KATAYAMA

IPC: G01N33/50 ,  C12N5/077 ,  C12N5/09

Abstract: A evaluation method of an anticancer drug includes culturing a cell structure containing a cancer cell and a stromal cell in a presence of one or two or more of anticancer drugs and evaluating an anticancer effect of the anticancer drug using, as an index, the number of cells having a proliferation ability of the cancer cell in the cell structure after the culturing, in which a signal transduction pathway in the cancer cell stimulated by a hepatocyte growth factor, a placental growth factor, or a vascular endothelial growth factor is more activated than a signal transduction pathway in a normal cell.

公开(公告)号：US20230329540A1

公开(公告)日：2023-10-19

申请号：US18245652

申请日：2021-09-16

Applicant: KAKEN PHARMACEUTICAL CO., LTD. ,  JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Yusuke Horiuchi

IPC: A61B1/273 ,  A61K38/48 ,  A61B1/06

CPC classification number: A61B1/2736 ,  A61K38/48 ,  A61B1/063 ,  A61K9/08

Abstract: For diagnosing gastric cancer by magnifying endoscopy with narrow-band imaging or endocytoscopy with narrow-band imaging where light of narrow-band width is used for observation, a high-performance diagnostic method was established. In place of staining with a dye conducted in other organs, pronase is orally administered prior to endoscopic examination and topically administered under endoscopic observation as needed. In this manner, endoscopy can be performed without promoting production of mucosal fluid. In conventional endoscopic examination, a lesion is found and definitive diagnosis is made based on pathological examination. In contrast, this method can provide high diagnostic performance, suggesting that accurate diagnosis equivalent to that provided by pathological examination can be made by endoscopy. Removal of mucosal fluid with pronase is useful in magnifying endoscopy and endocytoscopy.

公开(公告)号：US20230162356A1

公开(公告)日：2023-05-25

申请号：US17995592

申请日：2021-04-09

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  AI Medical Service Inc.

Inventor： Yusuke HORIUCHI ,  Tomohiro TADA

IPC: G06T7/00 ,  G06T7/70 ,  G06T11/00 ,  A61B1/00 ,  A61B1/06

CPC classification number: G06T7/0012 ,  G06T7/70 ,  G06T11/00 ,  A61B1/000096 ,  A61B1/0005 ,  A61B1/00055 ,  A61B1/063 ,  G06T2207/10068 ,  G06T2207/30096 ,  G06T2207/10016 ,  G06T2207/20081 ,  G06T2207/20084 ,  G06T2207/30092 ,  G06T2210/41

Abstract: Provided are a diagnostic imaging device, diagnostic imaging method, diagnostic imaging program, and learned model with which gastric cancer diagnosis can be carried out in real time during endoscopic examination performed using NBI in combination with a magnifying endoscope. The diagnostic imaging device comprises an endoscopic video image acquisition unit which emits narrow-band light at a subject's stomach and acquires an endoscopic video image captured while the stomach is in a state of magnified observation, and an estimation unit which uses a convolutional neural network, which has been caused to learn using gastric cancer images and non-gastric cancer images as training data, to estimate the presence of gastric cancer in the acquired endoscopic video image, and outputs estimation results.

公开(公告)号：US11414429B2

公开(公告)日：2022-08-16

申请号：US16314101

申请日：2017-06-30

Applicant: RIKEN ,  JAPANESE FOUNDATION FOR CANCER RESEARCH ,  KABUSHIKI KAISHA YAKULT HONSHA

Inventor： Minoru Yoshida ,  Hiroyuki Seimiya ,  Masayuki Okue ,  Yoko Yashiroda ,  Fumiyuki Shirai ,  Takeshi Tsumura ,  Yuko Kano ,  Kenichi Washizuka ,  Nobuko Yoshimoto ,  Yasuko Kouda ,  Takehiro Fukami ,  Tsubasa Chikada ,  Takashi Watanabe

IPC: C07D471/20 ,  C07D519/00 ,  C07D471/10 ,  C07D491/107

Abstract: Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

公开(公告)号：US20220178932A1

公开(公告)日：2022-06-09

申请号：US17605327

申请日：2020-04-15

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  OSAKA UNIVERSITY ,  TOSOH CORPORATION

Inventor： Koji UEDA ,  Naomi OHNISHI ,  Kazutake TSUJIKAWA ,  Norio NONOMURA ,  Motohide UEMURA ,  Kentaro JINGUSHI ,  Norihisa OHTAKE ,  Yasutoshi KAWAI

IPC: G01N33/574 ,  G01N33/535

Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).

公开(公告)号：US11152105B2

公开(公告)日：2021-10-19

申请号：US16249280

申请日：2019-01-16

Applicant: Sony Corporation ,  Japanese Foundation For Cancer Research

Inventor： Takeshi Ohashi

IPC: G16H30/20 ,  G06T3/00 ,  G06T5/50 ,  G02B21/36 ,  G06T11/00 ,  A61B6/00 ,  G06T7/00 ,  G06T7/30

Abstract: Provided is an information processing apparatus including an image supply unit that supplies a plurality of input images showing corresponding objects to an image processing unit and obtains a plurality of object images as an image processed result from the image processing unit, and a display control unit that synchronously displays the plurality of object images that have been obtained. The object images are regions including the corresponding objects extracted from the plurality of input images, and orientations, positions, and sizes of the corresponding objects of the plurality of object images are unified.

公开(公告)号：US11142801B2

公开(公告)日：2021-10-12

申请号：US15766631

申请日：2016-10-07

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  SEKISUI MEDICAL CO., LTD.

Inventor： Masami Arai ,  Sachio Nomura ,  Yuriko Nemoto ,  Takuya Yotani

IPC: C12P19/34 ,  C12Q1/6886 ,  G01N30/88 ,  G01N30/02 ,  C12Q1/68 ,  C12N15/09 ,  C12N15/00 ,  C12Q1/6806 ,  B01J20/281

Abstract: It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.

公开(公告)号：US20210122759A1

公开(公告)日：2021-04-29

申请号：US16497917

申请日：2018-03-29

Applicant: NAGASAKI UNIVERSITY ,  IWATE MEDICAL UNIVERSITY ,  JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Masatomo Iwao ,  Tsutomu Fukuda ,  Fumito Ishibashi ,  Yoshimasa Uehara ,  Naoyuki Nishiya ,  Yusukef Oku ,  Shingo Dan ,  Takao Yamori

IPC: C07D491/147

Abstract: Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EGFR) specific tyrosine kinase inhibitor, an agent for preventing and/or treating non-small cell lung cancer with resistance mutant EGFR and the like, and the like.
A compound represented by the formula (I): wherein X is O or NH, R1 and R2 are each independently a hydrogen atom or an optionally substituted hydrocarbon group; R3 and R4 are each independently a hydrogen atom, a halogen atom or an optionally substituted hydrocarbon group, and R5 and R6 are each independently an optionally substituted hydrocarbon group, excluding the following compounds: or a salt thereof.